glp 1 from china patent expiry and new GLP‑1 entries intensify global obesity drug fight China GLP-1 drug study suggests
Description
Semaglutide and Tirzepatide is not intended to treat obesity or diabetes
There is potential that GLP-1 therapy may benefit comorbidities and preclinical data on memory and dementia may be translatable to humans
A string of equipment recalls, executive reshuffles and strategic pivots followed
doi: 10.2337/cd19-0079 26 NauckMAStewartMWPerkinsCJones-LeoneAYangFPerryCet al
Choose Coordinated Care Fragmented treatment creates conflicting signals
LEWES, Del., July 15, 2026 (Newswire.com) - Quick disclosure before you read further: This is a paid advertorial
